IL6 and pulmonary arterial hypertension: Our studies may offer some explanation as to the aetiology of PASMC proliferation that may be of relevance to PAH onset and progression and, potentially a therapeutic option via intervention to target the hepcidin/ferroportin axis, or via IL-6 antagonists.